Novel Coronavirus Pneumonia (COVID-19)
Conditions
Interventions
Trial group:Qingfei Paidu Granule
Control group:Conventional treatment
Sponsors
Public Health Clinical Center of Chengdu
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: For the diagnosis of light and common COVID-19, refer to COVID-19 Diagnosis and Treatment Protocol (Trial Eighth Edition) (hereinafter referred to as "Diagnosis and Treatment Protocol"); Reference for asymptomatic infected persons: COVID-19 Control Plan (7th Edition). 1. Conform to the diagnostic criteria of mild, common COVID-19 and novel Coronavirus asymptomatic infection in the two protocols mentioned above; 2. To agree to participate in the study, the patient, legal guardian or the person in charge of the medical institution shall sign the informed consent through paper signature, mobile phone software electronic signature and voice authorization.
Exclusion criteria
Exclusion criteria: 1. Patients who cannot guarantee medication compliance during treatment and who are difficult to administer medication through oral nasal feeding; 2. Patients with severe primary respiratory disease, or other pathogenic microbiological pneumonia that needs to be differentiated from COVID-19 or Novel Coronavirus asymptomatic infection; 3. Patients with malignant tumors, mental diseases and other systemic malignancies who are considered unsuitable for the study by the investigator; 4. People who have been allergic or intolerant to the test drug; 5. Participating in other clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| duration of viral shedding;aggravation rate; | — |
Secondary
| Measure | Time frame |
|---|---|
| Routine blood;Biomedical indexes;Blood biochemical;The length of time;Imaging CT changes;The time for temperature to normalize;Blood oxygen saturation and oxygen absorption mode; | — |
Countries
China
Contacts
Public ContactWu Guihui
Public Health Clinical Center of Chengdu
Outcome results
None listed